Here, we constructed a novel DNA vaccine (XCL1-MS) that expresses XCL1, MUC1 and survivin fusion antigens to target cDC1, aiming to induce a robust CD8+T cell response to inhibit tumor development. The gene discussed is BIRC5; the disease is neoplasm.